Diastolic heart failure is defined clinically when signs and symptoms of heart failure are present in the presence of preserved left ventricular systolic function (ejection fraction >45%).

Adding Farxiga (dapagliflozin) to standard care significantly reduced the risk of death or worsening heart failure in older ...

Bristol Myers Squibb today announced that the U.S. Food and Drug Administration (FDA) has updated the U.S. Prescribing Information for CAMZYOS® (mavacamten, 2.5 mg, 5 mg, 10 mg, 15 mg capsules), ...

Researchers from Rutgers Health and RWJBarnabas Health have developed an artificial intelligence (AI) technology that ...

Bristol Myers Squibb today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic New York Heart Association (NYHA) class II-III ...

Princeton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has updated the U.S.

EBR Systems, Inc. (ASX: EBR) has received FDA approval of the WiSE® System, which marks a significant leap forward in the treatment of heart failure. Unlike conventional CRT, the WiSE System is the ...

It had been approved for hypertension. The new FDA labeling provides "for improving survival of stable patients with left ventricular systolic dysfunction (ejection fraction ≤40%) and clinical ...

Camzyos is an oral, selective allosteric and reversible inhibitor of cardiac myosin. It was approved in April 2022 for the treatment of adults with symptomatic New York Heart Association (NYHA) class ...

Vascular endothelial growth factor inhibitors (VEGFIs) have transformed treatment paradigms for several malignancies. By ...